Thursday, February 9, 2023
Market-Reporter
  • Home
  • Markets
    • U.S. Markets
    • Canada
    • Europe & Middle East
    • Emerging Markets
    • Asia
    • Latin America
  • Investing
    • Stocks
    • IPOs
    • Mutual Funds
    • ETFs
    • Bonds
    • Commodities
    • Currencies
    • Cryptocurrencies
  • Economy & Politics
    • Personal Finance
    • Spending & Saving
    • Retirement
    • Real Estate
No Result
View All Result
  • Home
  • Markets
    • U.S. Markets
    • Canada
    • Europe & Middle East
    • Emerging Markets
    • Asia
    • Latin America
  • Investing
    • Stocks
    • IPOs
    • Mutual Funds
    • ETFs
    • Bonds
    • Commodities
    • Currencies
    • Cryptocurrencies
  • Economy & Politics
    • Personal Finance
    • Spending & Saving
    • Retirement
    • Real Estate
No Result
View All Result
Market-Reporter
No Result
View All Result
Home IPOs

Femasys Inc. Announces Pricing of Initial Public Offering

MtR by MtR
June 18, 2021
in IPOs
0


ATLANTA, June 17, 2021 (GLOBE NEWSWIRE) — Femasys Inc., a biomedical company focused on transforming women’s healthcare by developing novel solutions and next-generation advancements providing significant clinical impact to address severely underserved areas, today announced the pricing of its initial public offering of 2,650,000 shares of its common stock at a public price of $13.00 per share. The gross proceeds to Femasys from the offering, before deducting the underwriting discounts and commissions and offering expenses, are expected to be $34.45 million. All of the shares are being offered by Femasys. In addition, Femasys has granted the underwriters a 30-day option to purchase an additional 397,500 shares of its common stock at the initial public offering price, less the underwriting discounts and commissions.

The shares are expected to begin trading on the Nasdaq Capital Market on June 18, 2021, under the ticker symbol “FEMY.” The offering is expected to close on June 22, 2021, subject to customary closing conditions.

Related articles

World’s largest duty-free retailer aims for Hong Kong’s biggest IPO of year – South China Morning Post

August 10, 2022

NSW Police dumps Bezos-backed Mark43 from core systems overhaul – Strategy – Security

August 10, 2022

Chardan and JonesTrading Institutional Services, LLC are acting as active joint book-running managers for the offering.

A registration statement relating to these securities was filed with the U.S. Securities and Exchange Commission (SEC) and was declared effective on June 17, 2021. Copies of the registration statement can be accessed through the SEC’s website at www.sec.gov. This offering is being made only by means of a written prospectus, forming a part of the effective registration statement. Copies of the final prospectus relating to the initial public offering can be obtained, when available, from: Chardan, Attention: Prospectus Department, 17 State Street, Suite 2100, New York NY 10004 or by email at prospectus@chardan.com; JonesTrading Institutional Services, LLC, Attention: Capital Markets, 757 Third Avenue, 23rd Floor, New York, NY 10017, or by email at compliance@jonestrading.com; or Broadridge Shareholder Services, c/o Broadridge Corporate Issuer Solutions, Inc., 1155 Long Island Avenue, Edgewood, NY 11717, Attn: IWS, or by telephone at (844) 998-0339, or by email at shareholder@broadridge.com.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Femasys
Femasys is a biomedical company focused on transforming women’s healthcare worldwide by developing novel solutions and next-generation advancements providing significant clinical impact to address severely underserved areas. With an initial focus in the area of reproductive health, its two lead product candidates offer solutions to improve patient care and health economics: FemBloc, a first and only non-surgical product for permanent birth control and FemaSeed, a first and only directed sperm delivery product for infertility treatment. Femasys’ FemVue product for fallopian tube assessment by ultrasound is currently marketed in the United States as its main commercial priority. Femasys has also developed a novel technology platform for tissue sampling intended to be marketed alongside our other women-specific medical products in the physician’s office setting.

Contacts

Investor Contact:

IR@femasys.com

Media Contact:

Media@femasys.com

Source: Femasys Inc.



Source link

Related Posts

World’s largest duty-free retailer aims for Hong Kong’s biggest IPO of year – South China Morning Post

by MtR
August 10, 2022
0

World’s largest duty-free retailer aims for Hong Kong’s biggest IPO of year  South China Morning Post Source link

NSW Police dumps Bezos-backed Mark43 from core systems overhaul – Strategy – Security

by MtR
August 10, 2022
0

Plans to replace NSW’s core policing system with a new cloud-based crime-fighting platform are in disarray after NSW Police terminated...

Syrma share sale to offer cues for IPO fence-sitters

by MtR
August 9, 2022
0

MUMBAI : The primary market will offer important cues to IPO-bound companies and investors this week. After a dry patch...

AIG eyes September as next window for unit’s IPO

by MtR
August 9, 2022
0

AIG, one of the world's biggest commercial insurers, on Monday blamed market volatility for the delay, becoming the latest company...

Gov. AbdulRazaq mourns Chief Imam of Ajase-Ipo

by MtR
August 9, 2022
0

The Governor said the death of the Chief Imam was a depletion in the rank of community leaders whose leadership...

Load More
  • Trending
  • Comments
  • Latest

Bank of England tells ministers to intervene on digital currency ‘programming’

June 21, 2021

Tips for checking smoke alarms during daylight saving time

March 12, 2022

GLOBAL MARKETS-U.S. stocks follow Europe up; Treasury yields rise, dollar firm

July 9, 2021

What will Durham County education bonds pay for? A full list

July 8, 2022
African currencies week ahead: Zambia's kwacha seen on back foot, Kenyan shilling up – Business Recorder

African currencies week ahead: Zambia's kwacha seen on back foot, Kenyan shilling up – Business Recorder

0
Maxum Foods releases Global Dairy Commodity Update for June

Maxum Foods releases Global Dairy Commodity Update for June

0
Letter: Perpetual bonds can help states fight hunger

Letter: Perpetual bonds can help states fight hunger

0
United Kingdom ETFs Are Riding the Re-Opening Momentum

United Kingdom ETFs Are Riding the Re-Opening Momentum

0

Investment in overseas real estate surges : The DONG-A ILBO

August 11, 2022

U.S. inflation CPI report, Wall Street, currencies

August 10, 2022

Alberta oil production set new record in first half of 2022

August 10, 2022

Industrial Lubricants Market to Reach $71 Billion by 2027.

August 10, 2022

Recent News

Investment in overseas real estate surges : The DONG-A ILBO

August 11, 2022

U.S. inflation CPI report, Wall Street, currencies

August 10, 2022

Alberta oil production set new record in first half of 2022

August 10, 2022

Categories

  • Asia
  • Bonds
  • Canada
  • Commodities
  • Cryptocurrencies
  • Currencies
  • Emerging Markets
  • ETFs
  • Europe & Middle East
  • IPOs
  • Latin America
  • Mutual Funds
  • Personal Finance
  • Real Estate
  • Retirement
  • Spending & Saving
  • Stocks
  • U.S. Markets
  • Privacy & Policy
  • About Us
  • Contact Us
  • Advertise with us

© 2021 Copyright Market-Reporter

No Result
View All Result
  • Home
  • Markets
    • U.S. Markets
    • Canada
    • Europe & Middle East
    • Emerging Markets
    • Asia
    • Latin America
  • Investing
    • Stocks
    • IPOs
    • Mutual Funds
    • ETFs
    • Bonds
    • Commodities
    • Currencies
    • Cryptocurrencies
  • Economy & Politics
    • Personal Finance
    • Spending & Saving
    • Retirement
    • Real Estate

© 2021 Copyright Market-Reporter